YUN JOHNSON
Pharmacy at Lake Dr, Milwaukee, WI

License number
Wisconsin 16811-40
Category
Pharmacy
Type
Pharmacist
Address
Address
2323 N Lake Dr, Milwaukee, WI 53211
Phone
(414) 291-1068
(414) 291-1073 (Fax)

Personal information

See more information about YUN JOHNSON at radaris.com
Name
Address
Phone
Yun Johnson, age 79
1754 Alfred Dr APT 3G, Luxemburg, WI 54217
Yun C Johnson, age 79
1754 Alfred Dr, Luxemburg, WI 54217
Yun C Johnson, age 79
5341 Edgewater Beach Rd, Green Bay, WI 54311

Professional information

Yun Johnson Photo 1

Gabaergic Agents To Treat Memory Deficits

US Patent:
2010013, May 27, 2010
Filed:
Aug 31, 2009
Appl. No.:
12/551149
Inventors:
James M. Cook - Whitefish Bay WI, US
Terry Clayton - Elm Grove WI, US
Yun Teng Johnson - Glendale WI, US
Sundari Rallapalli - Oak Creek WI, US
Dongmei Han - San Mateo CA, US
International Classification:
A61K 31/5517, A61P 25/00, C07D 487/04
US Classification:
514220, 540498
Abstract:
The present invention provides molecules and methods for the prevention and/or treatment of memory deficit related conditions and/or enhancement of cognition. In a preferred embodiment, the invention includes compounds, salts and prodrugs thereof for the prevention and/or treatment of these conditions.


Yun Johnson Photo 2

Gabaergic Receptor Subtype Selective Ligands And Their Uses

US Patent:
2012029, Nov 22, 2012
Filed:
Apr 27, 2012
Appl. No.:
13/458168
Inventors:
James M. Cook - Milwaukee WI, US
Terry S. Clayton - Colorado Springs CO, US
Hiteshkumar D. Jain - Kurla, IN
Yun Teng Johnson - Glendale WI, US
Jie Yang - Renssalaer NY, US
Michael Ming-Jin Poe - Milwaukee WI, US
Ojas A. Namjoshi - Cary NC, US
Zhi-jian Wang - Whitefish Bay WI, US
Assignee:
UWM RESEARCH FOUNDATION, INC. - Milwaukee WI
International Classification:
A61K 31/5517, A61P 25/18, A61P 25/22, A61P 25/08, C07D 487/04, C07D 487/14
US Classification:
514220, 540498, 540562, 540494, 514219
Abstract:
Described herein are α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as α3 or α2 or α2/α3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.